Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
The Hub & Spoke model is designed to extend advanced medical care to a wider community
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
Subscribe To Our Newsletter & Stay Updated